Materna Medical rebrands childbirth device and adds new investors to Series B2 funding
Ellora aims to reduce birth injury
Materna Medical, a California-based innovator in women’s pelvic health, has announced a further close within its ongoing $20 million Series B2 funding round —while also revealing a new commercial name for its investigational labor device, Ellora™.
This latest tranche is not a final close of the Series B2 round but marks the addition of three new investors: GLIN Impact Capital, Wealthing VC Club, and Citrine Angels. The round is led by InnovaHealth Partners, alongside returning investors Wavemaker Three-Sixty Health, Kimera Limited, Women's Venture Capital Fund, and Golden Seeds.
“As we celebrate the addition of these new funds to our investment team, we are also excited to announce the new commercial name for our second product, Ellora™ (formerly Materna Prep), aiming to transform the standard of care in labor and delivery,” said Tracy MacNeal, Chief Executive Officer of Materna Medical.
Reducing birth injury
Ellora™, an investigational device designed for use during labor, is intended to reduce pelvic floor muscle injury during vaginal delivery. The device is currently being evaluated in a randomized controlled trial known as the EASE trial, involving over 20 leading US hospitals. Results from this study are expected to form the basis of a De Novo submission to the US Food and Drug Administration later this summer.
Founded with the aim of addressing significant unmet needs in women’s pelvic health, Materna Medical estimates the addressable market for its technologies to be worth $25 billion. The company’s first commercial product, Milli™, a vaginal dilator for patients suffering from vaginismus and related conditions, launched in 2019. It received over-the-counter clearance from the FDA in 2023.
Materna’s work spans both preventive and therapeutic technologies across the OBGYN spectrum, and the company positions itself as a platform driving forward a new standard of care. Its team includes engineers, scientists, and commercial leaders united by the mission to empower women to protect their pelvic health.